wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 20. no 4. December 2015  
 TABLE OF CONTENT

 Review articles
New opportunities for the treatment of acute attacks of hereditary angioedema
Grzegorz Porębski

Hereditary angioedema (HAE) is a rare autosomal dominantly inherited
disease characterized by recurrent, self-limiting episodes of acute tissue
swelling. Management of HAE in the past was often limited to symptom
alleviation by means of painkillers and administration of fresh frozen
plasma. The situation changed radically with the implementation
of new disease-specific therapies whose efficacy has been confirmed in
clinical trials. Targeted therapies include recombinant human plasma C1
inhibitor as well as kallikrein-kinin system modulators, namely ecallantide
and icatibant. The latter is the latest therapeutic option available for
HAE patients in Poland. It disrupts bradykinin pathway by blocking BK2
receptors. The aim of this review is to update the practicing allergologists
and other health care providers on new advances in treatment of acute
attacks of HAE.

keywords: antagonista receptorów bradykininy, inhibitor C1, inhibitorkalikreiny, leczenie, wrodzony obrzęk naczynioruchowy, bradykinin receptor antagonist, C1 inhibitor, hereditary angioedema, kallikrein inhibitor, therapy

pages: from 236 to 238



estimated time of download (55 kB)
broadband speed:561282565121024[kbps]
time:124321[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.